Decort

Quick links to important sections

Decort

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Decort

What is Decort? Defining the Mineralocorticoid Drug Entity

Property Description
Active Ingredient Desoxycortone Pivalate (DOCP)
Form Microcrystalline aqueous suspension for injection
Pharmacological Class Mineralocorticoid / Corticosteroids for systemic use
General Purpose Hormonal replacement and electrolyte balance
Origin Synthetic steroid hormone (ester derivative)

Decort is a foundational synthetic mineralocorticoid medication specifically designed for hormonal replacement therapy. Its active ingredient is Desoxycortone Pivalate (DOCP), which functions as a substitute for essential mineralocorticoid hormones naturally produced in the adrenal glands. The compound belongs to the broader class of corticosteroids for systemic use. As an ester derivative, Desoxycortone Pivalate is engineered to be a long-acting molecule, providing sustained activity to ensure consistent hormonal support over an extended duration, a feature recognized in clinical practice for its reliable therapeutic profile.

Composition and Physical Form of Desoxycortone Pivalate

The medication is composed solely of the synthetic active ingredient Desoxycortone Pivalate suspended in an aqueous vehicle, defining it as a single active ingredient product. The official pharmaceutical form is a microcrystalline aqueous suspension for injection, meaning the substance is prepared as fine, solid particles suspended in liquid for administration. This specialized injectable medication form is required because the long-acting ester is designed to be slowly released from the site of injection, providing a continuous therapeutic action that cannot be achieved effectively via conventional oral administration.

General Purpose: Electrolyte and Fluid Regulation

The general therapeutic purpose of Decort is to restore and maintain the body's essential fluid and electrolyte balance. The mineralocorticoid activity primarily works by regulating the concentration of key minerals, such as sodium and potassium. By promoting the retention of sodium and water while increasing the excretion of potassium, the medication directly supports stable blood volume and pressure. This corrective action is fundamental to stabilizing basic metabolic and circulatory processes essential for maintaining overall system stability, which is clinically recognized as the primary therapeutic contribution of mineralocorticoid replacement.

Regulatory References

  1. EMA Authorisation Details for Zycortal (Desoxycortone Pivalate)

What side effects are possible with Decort?

Possible Side Effects and Safety Information

The officially documented safety profile of Desoxycortone Pivalate (Decort) is structured around high-level classifications of adverse reactions as established in governmental regulatory documents. The primary and most frequent effects observed relate to the drug's mineralocorticoid activity and its influence on fluid and electrolyte balance.

Adverse Reaction Frequency

Adverse reactions are formally categorized based on their rate of occurrence:

  • Very Common (occurring in ge 1 in 10 individuals): Increased thirst (Polydipsia) and increased urination (Polyuria).
  • Common (occurring in ge 1 in 100 individuals): Lethargy, decreased activity, depression, vomiting, diarrhea, alopecia, decreased appetite/anorexia, panting, and shaking/trembling.
  • Uncommon and Rare effects include pain at the injection site and, very rarely, pancreas disorders.

Systemic and Serious Reactions

The documented effects span several physiological systems, including the Urinary System (polyuria, inappropriate urination), the Gastrointestinal Tract (vomiting, diarrhea), and General Disorders (lethargy, tiredness).

Regulatory documentation also explicitly lists serious adverse reactions. These include the potential for anaphylaxis, collapse, and the aggravation of pre-existing congestive heart disease.

Safety Restrictions and Limitations

The official label contains safety restrictions related to pre-existing conditions. Use is contraindicated in individuals with known hypersensitivity to the active substance or in those suffering from congestive heart disease, severe renal disease, or edema. Safety has not been established for use during pregnancy or lactation.

Overdose and Emergency Response

Overdose and When to Seek Help

Decort (Dexamethasone) overdose is primarily defined by the duration and magnitude of exposure rather than a single acute event. A single massive overdose is generally not associated with acute life-threatening toxicity.

Overdose risk is significantly associated with chronic overuse or prolonged exposure to doses higher than prescribed. This long-term, high-dose exposure can lead to an exaggerated state of the drug’s known effects, including the development of a Cushingoid state (e.g., fluid retention, weight gain, hypertension) and adrenal suppression, where the body stops producing its own essential cortisol.

Documented Overdose Manifestations

Overdose Context Primary Manifestations
Acute (Single) Usually low risk; may show mild exaggeration of side effects.
Chronic (Prolonged) Cushingoid appearance, severe fluid retention, electrolyte disturbance (hypokalemic alkalosis), and psychiatric disturbances.

Emergency Actions

In all cases of suspected overdose, including chronic high-dose exposure, immediate medical attention is required. Contact a Poison Control Center or emergency services right away. Management is typically supportive and symptomatic, with clinical focus on addressing the hormonal and metabolic imbalances caused by prolonged high-dose use, such as discontinuing the medication under strict medical supervision to manage potential withdrawal effects.

Therapeutic Uses of Decort

What Decort Treats: Main Uses and Benefits

Decort (Desoxycortone Pivalate/DOCP) is a replacement therapy for mineralocorticoid hormones, generally used to support physiological stability. Its primary indication is commonly used for the long-term replacement therapy in cases of mineralocorticoid deficiency in primary hypoadrenocorticism (Addison’s disease).

Therapeutic Benefit and Core Symptom Domains

The medication is commonly used to help with symptoms related to systemic imbalance and circulatory volume depletion (hypovolaemia) that may occur in this deficiency. Decort's therapeutic role is to provide hormonal support, which contributes to the sustained control of the chronic condition and may assist with maintaining functional stability.

By assisting with the management of these imbalances, the medication is relevant for easing related symptoms that interfere with daily functioning, such as profound weakness and lethargy. The treatment is also applied in settings where short-term symptomatic assistance is needed, supporting patients during acute or disruptive episodes like an Addisonian crisis.

“The treatment is considered relevant for providing hormonal support to address systemic imbalances associated with chronic deficiency.”

Quick Fact: Relief for Systemic Imbalance Decort is applied in addressing the symptoms related to systemic imbalance, assisting with fluid and electrolyte management, which supports patients in coping more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Decort (dexamethasone) is a powerful corticosteroid and is strictly contraindicated for use in certain patient groups based on official regulatory documents.

Populations That Must Not Use Decort

Classification Condition/Group
Absolute Contraindication Hypersensitivity (allergy) to the active substance or any excipients.
Absolute Contraindication Systemic fungal infections.
Absolute Contraindication Live virus immunisation (vaccines) for individuals on immunosuppressive doses.

Restricted or Special Consideration Required

Specific populations require caution and close medical supervision due to heightened risks:

  • Active Infections: Use is generally prohibited in the presence of active viral diseases (e.g., active herpes simplex, varicella, shingles) or other infections unless specific anti-infective therapy is being given.
  • Medical History: Caution is mandatory for patients with a history of peptic ulceration, congestive heart failure, hypertension, uncontrolled psychoses, or ocular herpes simplex.
  • Pregnancy/Lactation: Use during pregnancy is allowed only when the benefit outweighs the potential risk to the fetus; infants of mothers who received substantial doses must be observed for signs of hypoadrenalism. Use while breastfeeding should be determined by a healthcare provider, balancing the benefits of therapy for the mother against the potential effects on the infant.
  • Older Adults: The elderly require close clinical supervision, as common side effects like osteoporosis and susceptibility to infection may have more serious consequences in this age group.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Desoxycortone Pivalate (Decort) focuses primarily on pharmacodynamic effects that alter the balance of electrolytes (sodium and potassium), which is the primary function of this mineralocorticoid replacement therapy.

Documented Pharmacodynamic Interactions

Interaction Type Interacting Substances/Agents
Caution Required (Electrolyte Effects) Medicines known to affect serum sodium or potassium concentrations, including Trimethoprim, Amphotericin B, Digoxin, and Insulin.
Reduced Effectiveness (Counteraction) Potassium-sparing diuretics (e.g., Spironolactone).

Co-administration with potassium-sparing diuretics is documented to reduce the intended therapeutic effect of Desoxycortone Pivalate by directly counteracting its activity of promoting potassium excretion and sodium retention. Therefore, concurrent use is often restricted. Furthermore, specific agents that influence serum electrolyte levels require cautious co-administration to manage potential additive effects on sodium and potassium balance.

Administration-Related Constraints

The product label contains specific procedural constraints related to the injectable form. Desoxycortone Pivalate must not be physically mixed in the same syringe with any other medicinal products. This restriction is documented due to the absence of compatibility studies between the suspension and other injectable preparations.

Mechanism of Action

Decort, a synthetic glucocorticoid, functions as an agonist for the intracellular glucocorticoid receptor (GR/NR3C1), which is expressed ubiquitously across numerous cell types, including lymphocytes, macrophages, and fibroblasts. Upon cell entry, Decort binds to the cytosolic GR, inducing a conformational change that causes the complex to dissociate from chaperone proteins and translocate into the nucleus.

Within the nucleus, the Decort-GR complex regulates gene transcription through two primary modes: transactivation and transrepression. By binding to Glucocorticoid Response Elements (GREs) on the DNA, the complex initiates transactivation, leading to the increased synthesis of anti-inflammatory proteins, such as Annexin A1 (lipocortin-1). Concurrently, the activated GR complex engages in transrepression by physically interacting with and inhibiting key pro-inflammatory transcription factors, including NF-kB and AP-1. This repression silences the gene expression of numerous inflammatory mediators, such as pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-alpha), chemokines, and adhesion molecules.

The net downstream cascade involves systemic modulation of immune and inflammatory pathways, including reduced leukocyte migration, decreased vascular permeability, suppression of lymphocyte proliferation, and alterations in metabolic processes such as gluconeogenesis.

Dosage and Administration Information

Decort contains Desoxycortone Pivalate (DOCP), and its official usage principles are defined by the regulatory documents for the only approved products containing this active ingredient. The usage protocol establishes a long-term administration schedule based on the drug’s extended-release nature, requiring specialized handling and monitoring.


Administration Scope

Field Detail
Route of Administration The microcrystalline suspension must be administered via Subcutaneous (SC) or Intramuscular (IM) injection. Intravenous injection is prohibited.
Dosing Schedule Initial dose is 2.2 mg/kg of body weight. Subsequent doses and injection intervals are adjusted based on measured serum Sodium/Potassium ( Na^+/ K^+) ratio to maintain electrolyte balance.
Preparation Requirements The vial must be thoroughly shaken just before drawing the dose to ensure the active microcrystalline suspension is uniformly dispersed.
Special Conditions The therapy requires concurrent daily administration of a glucocorticoid for complete hormonal replacement.

Official Procedural Structure

The administration follows a dynamic protocol designed for chronic management. After the required vial shaking, the calculated dose is administered via the approved injection route. The subsequent injection timing, which may range from 20 to over 30 days, is determined by monitoring electrolyte levels. The full regimen necessitates the concurrent use of a daily glucocorticoid to satisfy the need for dual hormonal replacement. This procedural structure defines the standardized approach for using the medication as outlined in regulatory documents.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Decort

Decort (Desoxycortone Pivalate/DOCP) has been studied for its use as a replacement therapy for mineralocorticoid hormones. The scientific understanding of this medication is primarily based on clinical trials and observational data reviewed by regulatory bodies. Research explores monitoring of certain physiological markers.


Evidence for Mineralocorticoid Replacement in Primary Hypoadrenocorticism

The research for Decort has centered on research explored its use in hormonal replacement for patients diagnosed with Primary Hypoadrenocorticism (Addison’s disease), a condition marked by insufficient mineralocorticoid production. Studies explored the use of Decort as a long-term strategy for this replacement need.

The main scientific evidence includes Controlled Clinical Field Trials and Randomized Controlled Trials (RCTs), alongside observational and retrospective analyses used to gather information over extended periods. These research scenarios primarily involved patients with the established deficiency, where studies examined how symptoms change over time. The controlled trials were often structured to compare patterns against alternative replacement treatments.


Evaluation of Electrolyte and Clinical Biomarkers

A core component of the research examined patterns related to key laboratory measurements focused on fluid and electrolyte balance. The trials examined changes in these critical markers.

The primary outcomes studied included measurement of serum sodium ( Na^+) and serum potassium ( K^+) concentrations, and the resulting Sodium-to-Potassium ratio ( Na^+/ K^+). Measurement of these electrolyte levels is a key focus in replacement therapy studies. Researchers also tracked Plasma Renin Activity (PRA) as an included biomarker.


Study Populations and Evidence Generalizability

The primary evidence base for Decort was evaluated in a specific population: patients diagnosed with Primary Hypoadrenocorticism. This research explored subjects who were newly diagnosed, as well as those who had been switched from other mineralocorticoid therapies.

A key factor in the research landscape is that the majority of high-quality, controlled evidence used for the official product label is derived from studies conducted in the veterinary domain (specifically, dogs with the condition). This means the results apply only to the populations studied and do not provide direct evidence for human use.


Research Gaps and Remaining Uncertainties

One significant limitation is that the sample sizes were modest in some of the key clinical trials. Furthermore, there is limited information for long-term outcomes in large studies spanning multiple years. The evidence quality varies across studies, with observational data providing necessary but less conclusive insights than controlled trials. Finally, the results apply only to the populations studied, meaning data for certain groups, such as children or older adults, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Decort (FAQ)


Q: What is the main difference between Decort and other similar prescription medicines?

Decort is a synthetic mineralocorticoid primarily used as a replacement therapy focused on maintaining the body's essential electrolyte balance (sodium and potassium). Official protocols describe Decort therapy as needing concurrent daily use of a separate glucocorticoid medication to achieve full hormonal replacement, highlighting the difference in their primary functions compared to medicines that may combine both activities.


Q: How long does it usually take for Decort to start working?

Decort is designed as a long-acting injectable suspension, meaning the active substance is released slowly over an extended period, often from 20 to over 30 days. Because of this formulation, the full effect is not immediate, and the medication works to maintain steady mineralocorticoid activity throughout the treatment interval.


Q: Is Decort the same as prednisone?

No, Decort is not the same as prednisone. Decort is classified as a mineralocorticoid replacement, while prednisone is a glucocorticoid. For complete hormonal replacement, official protocols describe the need for concurrent daily administration of a glucocorticoid alongside Decort.


Q: What happens when I stop taking Decort?

Decort is an essential replacement therapy intended for long-term use for a chronic condition. Regulatory documents indicate that abrupt discontinuation should be avoided, as the body relies on the medication to manage crucial electrolyte and fluid balance. Treatment management involves continual monitoring and adjustment of the maintenance schedule.


Q: Can Decort affect my vision?

As a type of corticosteroid, the drug class is generally associated with a potential for eye effects. Regulatory documentation notes that chronic use of this drug class may be a factor in the development of conditions like cataracts or glaucoma (increased pressure in the eye), for which ongoing monitoring is recommended.


Q: Is Decort safe for pregnant or breastfeeding individuals?

Official product information states that safety has not been definitively established for use during pregnancy or lactation. It may be used only when the expected clinical benefit is judged to outweigh the potential risk to the fetus or infant. Regulatory guidance specifies that infants of treated mothers must be observed for signs of hypoadrenalism (low adrenal function).


Q: What happens if I miss a dose of Decort?

Decort is administered on an extended schedule determined by monitoring electrolyte levels. A missed dose may lead to the recurrence of symptoms related to the underlying electrolyte imbalance. Treatment should continue to be managed according to the monitoring schedule as advised by a healthcare professional.


Q: Does taking Decort change how my body responds to vaccines?

The official product label states that live virus immunizations (vaccines) must be avoided while an individual is receiving an immunosuppressive dose of a corticosteroid. The product documentation does not provide specific information regarding the use of non-live, or inactivated, vaccines.


Q: Does Decort cause weight gain?

Yes, weight gain is listed as an adverse event that has been reported. Regulatory documents indicate that excessive weight gain may be a sign of fluid retention secondary to the medication's function of promoting sodium and water retention in the body.


Q: Is it okay to take Decort with over-the-counter pain relievers like ibuprofen or Tylenol?

Official warnings for the corticosteroid class note that concurrent use of corticosteroids with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) like ibuprofen is associated with a potential for increased risk of gastrointestinal adverse events, such as bleeding or ulceration. No specific warnings or interactions are documented for the co-administration of Decort with acetaminophen (Tylenol).


Q: Does Decort need to be taken with food?

Decort is a microcrystalline injectable suspension administered via subcutaneous or intramuscular injection, not an oral medication. Therefore, its administration is not dependent on food intake.


Q: What should I do if I feel sick after taking Decort?

The official safety profile lists symptoms such as vomiting and diarrhea as commonly reported adverse reactions. Regulatory guidance describes that clinical signs such as weakness, vomiting, or diarrhea may be indicators that the dose of the concurrent glucocorticoid medication needs adjustment.


Q: Why did my doctor prescribe Decort for this specific condition?

Decort is officially indicated for use as replacement therapy for mineralocorticoid deficiency. This treatment is specifically prescribed for patients diagnosed with Primary Hypoadrenocorticism, which is commonly known as Addison's disease.


Q: Can Decort affect my sleep?

The list of documented adverse reactions includes general effects such as lethargy, decreased activity, and depression. While specific sleep disorders like insomnia are not explicitly listed, these systemic effects may be related to changes in the patient's overall state of rest and energy.


Q: Does Decort make you feel tired or have low energy?

The adverse reaction listings include both lethargy (lack of energy or enthusiasm) and decreased activity as commonly reported effects. These are systemic effects that may contribute to a feeling of tiredness or low energy.


Q: Can Decort affect my mood or cause anxiety?

The regulatory documents list depression as a commonly reported adverse reaction associated with the medication’s use. They do not specifically list anxiety or other broad mood effects beyond depression.


Q: What information is available about long-term use of Decort?

Decort is indicated and designed for long-term, chronic administration as a replacement therapy. Long-term use requires ongoing medical supervision to monitor electrolyte balance and manage potential long-term effects, including those associated with fluid retention and bone health.


Q: Can older adults (seniors) use Decort?

Yes. Official warnings for this population emphasize the importance of close clinical supervision during treatment. This is due to the potential for common side effects like an increased susceptibility to infection and osteoporosis (bone weakening) to have more serious consequences in this age group.


Q: Is there any research on Decort's use in children?

The main evidence base used for the official product labeling was evaluated in a non-human population and does not provide direct evidence for human use. Regulatory documents indicate that data for certain human groups, such as children, currently remain insufficient.


Q: How do I know if Decort is working?

The effectiveness of Decort is determined by two main factors: the monitoring of serum sodium and potassium concentrations (electrolyte levels) through blood tests, and the overall clinical improvement of symptoms associated with the underlying condition, such as weakness and changes in urination and thirst.


Q: Why do some people say Decort makes them feel jittery?

The official adverse reaction list includes shaking/trembling as a commonly reported effect associated with the medication’s use. While 'jittery' is not an official medical term, the effect of shaking is documented in the product information.


Q: Does the effectiveness of Decort change over time?

The required dose and the interval between injections is dynamically adjusted over time based on monitored changes in the patient's electrolyte balance. This continuous adjustment is necessary to maintain the desired therapeutic effect over the long term.


Q: Why is Decort only available by prescription?

Decort is an injectable, long-acting hormonal replacement therapy intended for the chronic management of a serious medical condition (Primary Hypoadrenocorticism). Regulatory documents specify that it is restricted to use by or on the order of a licensed medical professional, reflecting the need for specialized monitoring during treatment.


Q: What does 'therapeutic benefit' mean regarding Decort's use?

The therapeutic benefit of Decort refers to the restoration of essential fluid and electrolyte balance. The drug's mineralocorticoid activity helps to maintain stable concentrations of key minerals like sodium and potassium, which in turn supports stable blood volume and pressure.


Q: Can Decort affect my bones or cause osteoporosis?

The official product warnings acknowledge that the risk of osteoporosis (bone weakening) is a concern associated with the use of the corticosteroid class of drugs. This risk is specifically highlighted in warnings for older individuals, who require close clinical supervision.


Q: Is Decort only for short-term use?

No. Decort is a long-acting medication specifically designed and indicated for the long-term, chronic management of mineralocorticoid deficiency. It is not intended for short-term or temporary use.


Q: Do I need to get blood tests while taking Decort?

Yes. Official documents describe the necessity for regular monitoring using blood tests. These tests measure the levels of serum sodium and potassium ( Na^+/ K^+) concentrations, and these measurements are crucial for determining the correct timing and dosage for subsequent injections.

How should Decort be stored and disposed of?

How to Store and Dispose of Decort

The storage and handling of Decort (Desoxycortone Pivalate injectable suspension) must strictly adhere to regulatory labeling to ensure product quality and stability.

Storage and Handling Requirements

Requirement Type Official Instruction
Temperature Store below 30 C. Do not freeze the product.
Child Safety Must be kept out of the sight and reach of children.
Stability (Opened Vial) Use within 4 months (120 days) after the vial is first punctured.
Handling The vial must be shaken gently before each use. Do not mix with other medicinal products.

️ Disposal Instructions

Any unused product or waste materials derived from the use of Decort must be disposed of in accordance with local requirements for pharmaceutical waste, as directed by official regulatory documents.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Decort found in:

A-Z Index: